October 31, 2022
Researchers at UC San Diego report that a polygenic hazard score based on 290 genetic variants could be an effective tool for predicting genetic risk of lethal prostate cancer, which kills more than 34,000 men in the U.S. annually.
November 16, 2015
Christopher J. Kane, M.D., a renowned specialist in prostate cancer and an expert in robotic and other minimally invasive procedures for urologic surgery at the University of California, San Diego, has been appointed the inaugural holder of the Joseph D. Schmidt, MD Presidential Chair in Urology in the School of…
November 16, 2011
Researchers at the University of California, San Diego School of Medicine and Kyushu University Medical School say a novel combination of a specific sugar molecule with a pair of cell-killing drugs prompts a wide variety of cancer cell types to kill themselves, a process called apoptosis or programmed cell death.
September 28, 2015
…reducing the burden of cancer among Hispanic/Latinos in San Diego and Imperial counties through research and community outreach has received a $13 million grant from the National Cancer Institute (NCI), part of the National Institutes of Health. The five-year grant renews funding for a partnership started in 2008 between San…
December 8, 2020
Compared to chimpanzees, our closest evolutionary cousins, humans are particularly prone to developing advanced carcinomas — the type of tumors that include prostate, breast, lung and colorectal cancers — even in the absence of known risk factors, such as genetic predisposition or tobacco use.
August 22, 2018
Christopher Kane, MD, has been appointed dean of clinical affairs for UC San Diego School of Medicine and CEO of UC San Diego Health Physicians, effective July 15. In these dual roles, Kane will collaborate with UC San Diego leadership to ensure that UC San Diego Health Physicians achieve the…
June 1, 2016
…imaging (MRI) to detect cancer but results of a University of California San Diego School of Medicine study describe the potential use of restriction spectrum imaging (RSI) as an imaging biomarker that enhances the ability of MRI to differentiate aggressive prostate cancer from low-grade or benign tumors and guide treatment…
April 30, 2014
…contributions to levels of these blood lipids and to prostate cancer.
April 27, 2016
…a new model of care for patients with low-risk prostate cancer. The evidence-based approach uses best practices to appropriately select and follow patients to avoid disease overtreatment. Results of the three-year study are now published online in the journal of Urology.
September 21, 2020
Moores Cancer Center at UC San Diego Health is using advanced imaging, genomics, personalized medicine and new therapies to treat patients like Brian McCloskey, who has stage IV prostate cancer.
